Remarks

• The GDG considered in vitro data demonstrating that casirivimab-imdevimab does not neutralize the currently circulating variants of SARS-CoV-2 and their subvariants.
• There was consensus among the panel that the meaningful reduction of in vitro neutralization activity strongly suggests absence of clinical effectiveness of monoclonal antibodies such as sotrovimab and casirivimab-imdevimab.
• There was also consensus regarding the need for clinical trial evidence in order to confirm clinical effectiveness of new monoclonal antibodies that reliably neutralize circulating strains in vitro.